<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P1132>	<http://www.wikidata.org/entity/statement/Q64802956-314DE507-EC09-48C2-80F1-DE3A7EE1E964> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P3098>	"NCT03489369" .
<http://www.wikidata.org/entity/Q64802956>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://wikiba.se/ontology#Item> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P6153>	<http://www.wikidata.org/entity/Q7896459> .
<http://www.wikidata.org/entity/Q64802956>	<http://schema.org/description>	"\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk .
<http://www.wikidata.org/entity/Q64802956>	<http://schema.org/description>	"clinical trial"@en .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P8363>	<http://www.wikidata.org/entity/statement/Q64802956-DF626265-0A25-4329-AA1C-0957CC74A827> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P1050>	<http://www.wikidata.org/entity/Q208414> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P582>	"2019-11-01T00:00:00Z"^^<http://www.w3.org/2001/XMLSchema#dateTime> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P1050>	<http://www.wikidata.org/entity/statement/Q64802956-6A39B5F8-A25C-4554-B421-7259711C9342> .
<http://www.wikidata.org/entity/Q64802956>	<http://schema.org/description>	"ensayu cl\u00EDnicu"@ast .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P2899>	<http://www.wikidata.org/entity/statement/Q64802956-F79D1A33-6B4B-4592-9585-EA82AE723109> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P6153>	<http://www.wikidata.org/entity/statement/Q64802956-2A46AE3F-0A4D-4D09-ABC2-D95B62ABA865> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.w3.org/2004/02/skos/core#prefLabel>	"Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas"@en .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P17>	<http://www.wikidata.org/entity/statement/Q64802956-9B31920F-3E11-472C-A771-427E45B65658> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P582>	<http://www.wikidata.org/entity/statement/Q64802956-DF616062-9565-430C-BCCA-1E6A2B0AD30C> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P580>	"2018-05-08T00:00:00Z"^^<http://www.w3.org/2001/XMLSchema#dateTime> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P1132>	"30"^^<http://www.w3.org/2001/XMLSchema#decimal> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P1476>	"A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas"@en .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P1476>	<http://www.wikidata.org/entity/statement/Q64802956-733D32FA-37E7-4753-9B03-954748B9A050> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P859>	<http://www.wikidata.org/entity/statement/Q64802956-B382E8E9-03F3-4425-BDED-EDDE92BE8348> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P3098>	<http://www.wikidata.org/entity/statement/Q64802956-0DE7F4C9-903F-4E5D-8D4A-AD895BAF65B9> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P31>	<http://www.wikidata.org/entity/statement/Q64802956-A1E39235-C6A5-40CE-8738-A6E57D3354DE> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P17>	<http://www.wikidata.org/entity/Q30> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P580>	<http://www.wikidata.org/entity/statement/Q64802956-A3772D52-0CFB-40A1-9129-6B278A2C738A> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P17>	<http://www.wikidata.org/entity/statement/Q64802956-6A00B6FA-2D69-400B-AEF0-A18E92A0A5DA> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P31>	<http://www.wikidata.org/entity/Q30612> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P859>	<http://www.wikidata.org/entity/Q7661403> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.w3.org/2000/01/rdf-schema#label>	"Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas"@en .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P6099>	<http://www.wikidata.org/entity/Q5452194> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/P6099>	<http://www.wikidata.org/entity/statement/Q64802956-5404D6AD-D262-40DC-BA6D-C1A93C2045F1> .
<http://www.wikidata.org/entity/Q64802956>	<http://schema.org/name>	"Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas"@en .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P8363>	<http://www.wikidata.org/entity/Q78089383> .
<http://www.wikidata.org/entity/Q64802956>	<http://schema.org/description>	"klinisch onderzoek"@nl .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P2899>	"18"^^<http://www.w3.org/2001/XMLSchema#decimal> .
<http://www.wikidata.org/entity/Q64802956>	<http://www.wikidata.org/prop/direct/P17>	<http://www.wikidata.org/entity/Q16> .